• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

High Throughput Screening Assays for Drug Discovery

by Bellbrook Labs / Tuesday, 23 July 2019 / Published in HTS Assays
High Throughput Screening Assays for Drug Discovery

The world of drug discovery is exciting, yet challenging. High throughput screening assays (HTS Assays) have changed scientific research and biological testing, allowing for greater efficiency and lower costs. 

This is just one case where automation has paid off. Just ask the scientists that aren’t doing repetitive pipetting, doctors getting faster testing results, or patients who have received life-changing therapeutics. Being able to test multiple patient samples for a particular disease in one plate (microplates come in 96, 192, 384, 1536, or 3456+ wells)  is an amazing freat of automation. 

But, where automation has really come in handy is drug discovery. Otherwise finding active compounds to combat one explicit aliment would be more painstaking than finding a needle in a haystack. It’s not impossible, but a lot more time consuming and costly.

High Throughput Screening Assays Make it Easier to Find the Needle in the Haystack

High Throughput Screening Assays Make it Easier to Find the Needle in the Haystack

Phenotypic vs. Biochemical Approach to High Throughput Screening

There are different approaches when it comes to HTS assays which should be chosen depending on the goals of the researcher. While target-based drug discovery (TDD) determines how a specific compound interacts with a target, phenotypic screening compares several compounds to find the one that results in the desired phenotype. 

Phenotypic screens are cell-based such as proliferation assays to determine how a drug affects cell growth. Moreover, TDDs are often biochemical such as enzymatic kinase activity assays. These establish the amount of kinase activity to find small molecule enzymatic modulators within compound libraries. Both target and cell-based screening methods have contributed immensely to drug discovery, by producing high-quality data.

HTS and Hit-to-Lead

The hit-to-lead drug discovery process using high throughput screening assays can be divided into several steps. These include target identification, assay design, primary and secondary screens, data processing, analysis, and identification of hits (compounds that meet the desired effect).¹ Each statistical parameter is valuable to the drug screening process. 

These are just the first steps in drug discovery as potential hits need to be investigated further in a hit-to-lead program. All steps have their own challenges to overcome in order to move the lead to clinical trials and bring a drug to market. 

HTS Compound Libraries

Regardless of the approach and assay technologies used for HTS, a chemical library is used to examine potential novel drugs. These compound libraries vary from being general with thousands of small molecules to a more specifically tailored to a family of related targets (such as kinases, voltage-gated ion channels, and serine/cysteine proteases).²

Currently, there are a ton of libraries to select from. Some commercial companies specialize in creating these libraries, while other libraries are generated internally by pharmaceutical companies. False positives and PAINS are important to eliminate as much as possible. Having a quality library is necessary to streamline the process.

Compound Libraries HTS Assays

Compound Libraries Store Vast Amounts of Potential New Drugs

So…You Have a Hit, Now What?

Due to the nature of screening thousands of compounds at once, a post HTS analysis is necessary to hone in on possible candidates. Multiple factors can be determined such as IC50 (effectiveness drug has on inhibiting target) and residence time (amount of time that drug is bound to target) to decide whether to move forward with a potential drug.

Universal Transcreener High Throughput Screening Assays are well-suited to test for potency and residence time since the detection reagents can be added directly to an enzyme reaction. Measuring activity in kinetic mode makes it convenient to examine enzyme activity and time residence for several molecules with the same assay.³  

SAR (structure-activity relationships) refers to exploring the relationship between the structure of a molecule and its biological activity, making it a useful method for narrowing the list.4

Some researchers use computational methods to come up with likely hits. They can then perform follow up SAR analysis with biochemical assays to ensure the molecule behaves with the target as predicted.

It isn’t enough to identify molecules that elicit the preferred effect. Is it a potent, stable drug or does it cause toxicity? Can it be used in humans without major side effects? These questions need to be addressed before moving forward with drug development and clinical trials.

High Throughput Screening Assays Provide A Flexible, Proven Method for Drug Discovery

What’s better than being capable of testing hundreds of samples at once? One assay design for multiple projects. Universal biochemical assays such as Transcreener are capable of testing multiple targets due to their flexible design (e.g. Transcreener ADP² Assay for virtually any kinase).

Since they use a fluorescence format to detect biochemical activity, the instrumentation is easy to come by as long as it’s capable of performing fluorescence polarization (FP), fluorescence intensity (FI), or TR-FRET formats. 

Discovering new drugs is a long and tedious process. With HTS, the process is more proficient. However, there are still many steps that need to be carefully monitored along the way in order to bring a valuable and potent novel drug to market.

References

  1. Shukla AA. High Throughput Screening of Small Molecule Library: Procedure, Challenges and Future. 2016;5(2):3-5. doi:10.15406/jcpcr.2016.05.00154. https://medcraveonline.com/JCPCR/JCPCR-05-00154.php
  2. Hajare AA, Salunkhe SS, Nadaf SJ. Review On: High-Throughput Screening Is An Approach To Drug Discovery. 2013;(August 2014). https://www.academia.edu/11249102/Review_on_High-throughput_screening_is_an_approach_to_drug_discovery
  3. BellBrook Labs, A Guide to Measuring Drug-Target Residence Times with Biochemical Assays. https://www.bellbrooklabs.com/get-residence-time-guide/
  4. Sittampalam GS, Coussens NP, Brimacombe K, et al. Assay Guidance Manual. 2019;(Md). https://www.ncbi.nlm.nih.gov/books/NBK53196/
Tagged under: High Throughput Screening Assays, HTS Assays

What you can read next

Ectonucleotidases: An Outside Chance for Drug Development
Glycosyltransferase Activity Assay and Lysosomal Storage Disorders
Using a Glycosyltransferase Activity Assay to Study Glycosylation and the Function of GTs
Previously Recorded Webinar – The New AptaFluor™ SAH Methyltransferase Assay: A Homogenous, Universal Assay Based on a Microbial Riboswitch

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP